Beta-blockers versus digoxin to control ventricular rate during atrial fibrillation.

نویسندگان

  • Henrique H Veloso
  • Angelo A V de Paola
چکیده

Ezekowitz et al. (1) recently reported lack of benefit of angiotensin-converting enzyme (ACE) inhibitors on mortality in patients with chronic heart failure (CHF) in whom estimated creatinine clearance was below 60 ml/min, as opposed to a beneficial effect in those with creatinine clearance above 60 ml/min. The researchers attribute this lack of benefit to a possible interaction between aspirin and ACE inhibitor use, suggesting that aspirin might blunt the effects of ACE inhibitors. Whereas this might be true, in our opinion another explanation should be considered as well, namely prescription bias. In CHF, ACE inhibition should be prescribed to all patients, especially in those with severe CHF. Regretfully, this is not always true in daily practice. In the cohort studied by Ezekowitz et al. (1), only 60% were using ACE inhibitors. It has been reported that physicians are reluctant to prescribe ACE inhibitors in the presence of severe renal dysfunction (2). Physicians are more willing to prescribe ACE inhibitors to CHF patients if such patients are more symptomatic (3). In CHF, renal function impairment can elicit a clinically more unstable condition—for instance, by fluid retention. Accordingly, in the present study by Ezekowitz et al. (1), confounding by prescription may have occurred among the patients with renal function impairment, with ACE inhibitors being preferentially prescribed to subjects with a more unstable cardiac condition and a worse prognosis. In view of the prognostic importance of renal function in subjects with CHF, it might be relevant that, in subjects with primary renal disease and severely impaired renal function, ACE inhibition protects against further worsening of renal function (4). Whether this might be of benefit in CHF patients has not been studied so far. Taken together, the data by Ezekowitz et al. (1) argue for prospective studies into the role of ACE inhibitors in CHF subjects with renal function impairment.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

اسید آسکوربیک خوراکی به همراه بتا بلوکرها روشی موثر برای کاهش فیبریلاسیون دهلیزی به دنبال عمل جراحی بای پس عروق کرونر

Background: Adrenergic beta antagonists are not sufficient to prevent atrial fibrillation after coronary artery bypass graft (CABG). This study was designed to evaluate the effect of ascorbic acid as an adjunct to beta-blockers in prevention of post-CABG atrial fibrillation Methods: Patients who were more than 50 years old and scheduled to undergo CABG were included if they were treated with b...

متن کامل

Intravenous Amiodarone versus Digoxin in Atrial Fibrillation Rate Control; a Clinical Trial

INTRODUCTION Treatment of rapid ventricular response arterial fibrillation (rapid AF) varies depending on the decision of the in-charge physician, condition of the patient, availability of the drug, and the treatment protocol of the hospital. The present study was designed aiming to compare IV digoxin and amiodarone in controlling the heart rate of patients presenting to emergency department wi...

متن کامل

Digoxin for patients with atrial fibrillation and heart failure: paradise lost or not?

Digoxin is one of the oldest drugs in cardiovascular medicine, and it was traditionally used in patients with atrial fibrillation (AF) and heart failure (HF). In the last 20 years, the use of this drug has markedly declined, and in the most recent 2012 European Society of Cardiology (ESC) HF Guidelines, it is stated that for patients with HF and a left ventricular ejection fraction (LVEF) ≤40%,...

متن کامل

Digoxin in heart failure and cardiac arrhythmias.

HEART FAILURE Digoxin therapy has no effect on mortality in heart failure. Digoxin may be useful for maintaining clinical stability and exercise capacity in patients with symptomatic heart failure. Digoxin appears to be of most benefit in patients with severe heart failure, cardiomegaly and a third heart sound. Digoxin should be used as a second-line drug after diuretics, angiotensin-converting...

متن کامل

Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure?

OBJECTIVES This study examined the relative merits of digoxin, carvedilol, and their combination for the management of patients with atrial fibrillation (AF) and heart failure (HF). BACKGROUND In patients with AF and HF, both digoxin and beta-blockers reduce the ventricular rate, and both may improve symptoms, but only beta-blockers have been shown to improve prognosis. If combined therapy is...

متن کامل

Chronic atrial fibrillation: a systematic review of medical heart rate control management.

OBJECTIVE Recent guidelines by the National Institute for Health and Clinical Excellence (NICE) and the American College of Cardiology/American Heart Association/European Society of Cardiology (ACC/AHA/ESC) on rate control management for chronic atrial fibrillation have relegated digoxin to second line treatment, recommending instead the use of beta-blockers or rate limiting calcium antagonists...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Journal of the American College of Cardiology

دوره 45 11  شماره 

صفحات  -

تاریخ انتشار 2005